2 research outputs found
Clinical outcomes of assisted reproductive technology treatment by using a selfâinjection of recombinant human chorionic gonadotropin as the final maturation trigger
Abstract Purpose To evaluate the efficacy and safety of selfâinjections of the prefilled recombinant human chorionic gonadotropin (râhCG) in a syringe in assisted reproductive technology (ART) treatment for the maturation trigger (MT), as compared to selfâinjections of conventional hCG and intranasal administration of gonadotropinâreleasing hormone agonist (GnRHâa). Methods Between January and April, 2017, 396 patients who underwent oocyte retrieval were recruited. Of these, 396 patients were classified into three groups, according to the types of MT: (1) the urinary human chorionic gonadotropin (uâhCG) group that consisted of patients who had a selfâinjection of uâhCG (n = 127); (2) the GnRHâa group that received nasal administration of GnRHâa (n = 159); and (3) the râhCG group that had a selfâinjection of râhCG (n = 110). Several ART outcomes were evaluated. Results The mature oocyte retrieval rate was not different between the uâhCG, râhCG, and GnRHâa groups and the fertilization and cleavage rates were similar between the three groups. The clinical pregnancy rates did not significantly differ between the GnRHâa group and the uâhCG group; however, it was significantly lower in the GnRHâa group, compared to the râhCG group. No difference was observed in the incidence of moderate or more severe ovarian hyperstimulation syndrome among the three groups. Conclusion The selfâinjection of the prefilled râhCG is a favorable MT for ART patients